Pawel Przewiezlikowski, Ryvu Therapeutics CEO
August 17, 2022 09:10 AM EDTUpdated 10:48 AM
Financing

Up­dat­ed: EU­'s lend­ing arm grants Pol­ish biotech $22M+ in debt fi­nanc­ing to ad­vance pipeline

Paul Schloesser

Associate Editor

Many US biotechs have been tight­en­ing their pock­et­books in an ef­fort to keep them­selves run­ning. But over in Poland, one com­pa­ny is nab­bing a debt …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times